DIMOND - ongoing, but no longer recruiting participants

The Huntington Study Group (HSG) is conducting a study of the research medication Dimebon in persons 29 years of age or older who have mild to moderate Huntington disease (HD). DIMOND is designed to determine safe and tolerable doses of Dimebon and also to determine the effect of Dimebon on cognitive (thinking) and motor (movement) signs and overall functioning of subjects with HD. Approximately 15 research centers in the United States and in the United Kingdom enrolled about 90 research subjects. The entire time on study drug will last about 3 months. The study enrolled research subjects with early to moderate signs of HD who are independently ambulatory (walking) and self-sufficient in activities of daily living, such as eating, dressing, and bathing. Enrollment began in the Summer of 2007, and was completed in March 2008. The study is sponsored by Medivation, Inc.